Gut microbiome and incidence of major adverse cardiovascular events in the general population: a prospective study in five European cohorts

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Background

Accumulating evidence suggests that the gut microbiota is implicated in cardiovascular disease. We investigated how the gut microbiome associates with incident major adverse cardiovascular events (MACE), and cardiovascular and all-cause mortality (ACM) in a large, prospective, population-based study. The findings were tested for replication in four independent cohorts.

Methods

Gut microbiome composition was assessed via shallow shotgun sequencing in the FINRISK 2002 cohort, with up to 18 years of follow-up. Associations of microbial taxa with incident MACE were investigated using time-to-event analyses. Significant associated microbial features were tested for replication in four European cohorts (HUNT, HELIUS, SIMPLER, and SCAPIS) followed by a meta-analysis.

Results

In the FINRISK 2002 cohort (1167 incident MACE events), nine taxa were significantly associated with incident MACE and sustained adjustments for traditional risk factors and multiple comparisons. The meta-analysis of replication cohorts (N=30,228; 1,938 participants with incident MACE) confirmed robust associations for several identified taxa. Specifically, higher abundance of genera Scardovia (HR=1.17 [95% CI 1.08-1.26] , p = 0.0001) and Limosilactobacillus (HR=1.16 [95%CI 1.09-1.23] , p = 1E-06) was associated with increased MACE risk, and increased risk of cardiovascular mortality and all-cause mortality. The species ER4 sp900317525 (HR=0.89 [95%CI 0.83-0.95], p =0.0005) was associated with lower hazard of MACE and all-cause mortality.

Conclusions

The gut metagenome showed robust associations with incident MACE, which were replicated in four independent European cohorts. Key microbial taxa also associated with incident MACE and mortality, suggesting their potential relevance as candidate risk markers for further studies.

Clinical Perspective

What is New?

  • In a large-scale discovery and replication study involving five European population-based cohorts (> 36,000 participants) we identified specific gut microbial taxa—including the genera Scardovia and Limosilactobacillus - which were significantly associated with increased risk of major adverse cardiovascular events (MACE).

  • The obligate anaerobic commensal ER4 sp900317525 , member of the Oscillospiraceae family, was associated with a lower risk of incident MACE across independent cohorts.

  • These microbial signatures remained significant after adjusting for traditional cardiovascular risk factors and were further associated with both cardiovascular and all-cause mortality.

What Are the Clinical Implications?

  • The gut microbiome may represent a novel and modifiable risk factor for MACE as well as cardiovascular- and all-cause mortality.

  • These findings provide a rationale for future clinical trials investigating whether targeted modulation of the gut microbiome—through diet, prebiotics, oral hygiene, or other targeted therapies—can reduce the risk of MACE and improve patient survival.

Article activity feed